Inflammatory and T Helper 17/ Regulatory T Cells Related Cytokines Balance in Cutaneous Lupus Erythematosus (CLE)
- PMID: 32245325
- DOI: 10.18502/ijaai.v19i1.2411
Inflammatory and T Helper 17/ Regulatory T Cells Related Cytokines Balance in Cutaneous Lupus Erythematosus (CLE)
Abstract
The cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus erythematosus (SLE) patients. Malar rash and discoid lupus (DLE) are in the category of acute and chronic CLE, respectively. The pathogenesis of CLE is multifactorial, and cytokine imbalances contribute to immune dysfunction and the induction of organ damage. Many aspects of cytokine dysregulation are still unclear in SLE and in particular CLE. Therefore, we concurrently measured the inflammatory [Tumor necrosis factor-alpha (TNF-α) and Interleukin (IL)-6)], T helper (Th)-17 (IL-17 and IL-23) and regulatory T cells [Transforming growth factor-beta (TGFβ) and IL-10)]-related cytokines in patients with CLE (patients with malar rash and/or DLE) and compared them with SLE patients and healthy individuals (n=25 in each group, a total of 75 patients). The serum levels of cytokines were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. IL-6 cytokine was significantly higher in SLE, DLE, and malar rash patients compared to those in healthy controls (p=0.025) and in patients with arthralgia (p=0.038), and gastrointestinal involvement (p=0.048). IL-17 was significantly higher in malar rash patients compared to normal individuals (p=0.023), SLE (p=0.008) and DLE patients (p=0.019) and in patients with oropharyngeal ulcer (p=0.05) but, IL-23 was significantly higher only in DLE patients than healthy controls (p=0.019). In conclusion, inflammatory cytokines such as IL-6 involved in inflammation and differentiation of Th17 cells are probably responsible in part for Th17 activity in CLE. IL-17, IL-23, and IL-6/IL-6R (IL-6 receptor) inhibitors may be good treatments for CLE patients. So targeting these cytokines activity pathways can improve the CLE treatment strategy and may open a novel guideline for SLE and CLE treatment.
Keywords: Cutaneous lupus erythematosus; Inflammatory cytokines; Regulatory T cells; T helper 17.
Similar articles
-
Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.Cytokine. 2015 Apr;72(2):146-53. doi: 10.1016/j.cyto.2014.12.027. Epub 2015 Jan 31. Cytokine. 2015. PMID: 25647269
-
Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.Autoimmun Rev. 2017 Jul;16(7):735-742. doi: 10.1016/j.autrev.2017.05.009. Epub 2017 May 5. Autoimmun Rev. 2017. PMID: 28483542 Review.
-
Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study.Lupus. 2016 Apr;25(4):376-81. doi: 10.1177/0961203315610645. Epub 2015 Oct 8. Lupus. 2016. PMID: 26453664
-
Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus.Cytokine. 2019 Jul;119:95-112. doi: 10.1016/j.cyto.2019.03.010. Epub 2019 Mar 20. Cytokine. 2019. PMID: 30903869
-
The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.Cytokine. 2015 Jun;73(2):326-34. doi: 10.1016/j.cyto.2015.01.031. Epub 2015 Mar 9. Cytokine. 2015. PMID: 25767072 Review.
Cited by
-
Follicular Regulatory T Cells in Systemic Lupus Erythematosus.J Immunol Res. 2021 Jul 13;2021:9943743. doi: 10.1155/2021/9943743. eCollection 2021. J Immunol Res. 2021. PMID: 34337086 Free PMC article. Review.
-
Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus.Int J Mol Sci. 2022 Sep 14;23(18):10706. doi: 10.3390/ijms231810706. Int J Mol Sci. 2022. PMID: 36142624 Free PMC article. Review.